Related Experiment Video

Updated: Aug 24, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Epothilones: mechanism of action and biologic activity

Susan Goodin1, Michael P Kane, Eric H Rubin

  • 1Department of Medicine, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, USA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|May 15, 2004
PubMed

Insights

New epothilone anticancer drugs show promise by stabilizing microtubules, offering an alternative to taxanes and demonstrating effectiveness against resistant tumors in early clinical trials.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Microtubule-targeting drugs are crucial in cancer therapy.
  • Existing taxane therapies face challenges like resistance and administration issues.
  • New compounds aim to overcome these limitations.

Purpose of the Study:

  • To evaluate epothilones as a novel class of microtubule-targeting anticancer agents.
  • To assess their efficacy in preclinical models, including those resistant to paclitaxel.
  • To review early clinical data for specific epothilone compounds.

Main Methods:

  • Preclinical studies involving microtubule stabilization assays.
  • Testing epothilones in paclitaxel-resistant tumor models.
  • Analysis of Phase I and early Phase II clinical trial data for BMS-247550, BMS-310705, EPO906, and KOS-862.

Main Results:

  • Epothilones bind and stabilize microtubules, similar to but distinct from paclitaxel.
  • These compounds demonstrate efficacy in paclitaxel-resistant cancer models.
  • Early clinical data indicate broad antitumor activity with manageable side effects.

Conclusions:

  • Epothilones represent a promising new class of anticancer drugs.
  • They offer a potential alternative to taxanes, overcoming resistance mechanisms.
  • Further clinical development is warranted based on early positive results.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.